Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

BATS BZX Real-Time Price
As of 3:51pm ET
 +0.05 / +0.47%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Tetraphase Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant and gram-negative infections. The company's lead product candidate, eravacycline is a fully synthetic tetracycline derivative that is developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. It has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Contact Information

Tetraphase Pharmaceuticals, Inc.
480 Arsenal Street
Watertown Massachusetts 02472
P:(617) 715-3600
Investor Relations:
(617) 600-7040



Mutual fund holders47.16%
Other institutional34.56%
Individual stakeholders31.06%

Top Executives

Guy MacDonaldPresident, Chief Executive Officer & Director
John Craig ThompsonChief Operating Officer
David Charles LubnerChief Financial Officer & Senior Vice President
Patrick Taylor HornChief Medical Officer
Maria D. StahlSenior Vice President & General Counsel